Illumina has acquired SomaLogic, enhancing its presence in the proteomics market and expanding its multiomics capabilities to support faster drug discovery.

Target Information

Illumina, Inc. (NASDAQ: ILMN) has successfully acquired SomaLogic, a prominent player in data-driven proteomics technology. This acquisition enhances Illumina's existing multiomics portfolio, offering customers improved access to proteomic insights that can expedite drug discovery processes and contribute positively to healthcare advancements. SomaLogic's innovative capabilities are expected to play a vital role in this transition.

SomaLogic specializes in advanced technologies that provide deep insights into protein functions, interactions, and modifications. This understanding is critical for unraveling complex biological systems and human health issues. The integration of SomaLogic's offerings with Illumina's established technologies promises to yield comprehensive multiomic datasets, thereby empowering customers to select tools and workflows that best fit their research needs.

Industry Overview in the Target’s Country

The proteomics market has been experiencing significant growth, underpinned by advancements in technology and increasing research investments. Proteomics, the large-scale study of proteins, is pivotal in the fields of dr